kempharm buyout
「kempharm buyout」熱門搜尋資訊
「kempharm buyout」文章包含有：「KemPharmAnnouncesCorporateNameChangetoZevra...」、「KemPharmAnnouncesStrategicAcquisitionofArimoclomol...」、「KemPharmIssuesLettertoShareholders」、「KemPharmrebrandstoZevraTherapeutics」、「CORRECTION–KemPharmAnnouncesCorporateName...」、「KemPharmAcquiresMajorityofOrphazymeAssetsUnder...」、「KemPharm(KMPH)StockUponDealtoAcquire...」、「KemPharmChangesNametoZevraTherapeutics」、「KemPharm...
查看更多
KemPharm Announces Corporate Name Change to Zevra ...
https://www.biospace.com
In May 2022, Zevra, then KemPharm, acquired arimoclomol, an orally-delivered, first-in-class investigational product candidate for the treatment ...
KemPharm Announces Strategic Acquisition of Arimoclomol ...
https://investors.kempharm.com
Under the terms of the agreement, KemPharm will purchase substantially all of the assets and operations of Orphazyme, including arimoclomol, for ...
KemPharm Issues Letter to Shareholders
https://investors.kempharm.com
KemPharm's acquisition of arimoclomol in May 2022 , as well as substantially all of the assets and operations of Orphazyme, was a ...
KemPharm rebrands to Zevra Therapeutics
https://www.mmm-online.com
KemPharm's rebranding to Zevra marks its increased focus on the rare diseases space, the company announced.
CORRECTION – KemPharm Announces Corporate Name ...
https://investors.zevra.com
“With the launch of our new company name in anticipation of Rare Disease Day next week, we renew our unwavering commitment to stand with this ...
KemPharm Acquires Majority of Orphazyme Assets Under ...
https://www.biospace.com
KemPharm will pay Orphazyme around USD$12.8 million for all of its assets and take on Orphazyme's debts, which are estimated to be USD$5.2 ...
KemPharm (KMPH) Stock Up on Deal to Acquire ...
https://www.nasdaq.com
With the latest deal, KemPharm is looking to acquire Orphazyme's arimoclomol, an orally-delivered, first-in-class heat shock protein amplifier, ...
KemPharm Changes Name to Zevra Therapeutics
https://www.americanpharmaceut
Zevra Therapeutics, Inc. is the new name of KemPharm, Inc., reflecting the company's renewed focus on developing transformational therapies ...
KemPharm Inc (KMPH) builds on repurposing molecules
https://www.linkedin.com
Mitton believes that KemPharm has positioned itself to be “a prime buyout candidate or a strong successful go-it-alone entity. The choice is ...